Our results are consistent with previous reports indicating comparable SV2A expression levels in the middle frontal gyrus of AD patients and NCs via ELISA and Western blotting [69], whereas immunostaining studies (with smaller sample sizes of n = 6–7 per group) have reported reductions of both SV2A and SYP in the middle as well as inferior frontal gyrus of AD patients [70]. Here, SV2A is linked to Alzheimer disease.